Mani Foroohar
Stock Analyst at Leerink Partners
(1.48)
# 3,157
Out of 4,765 analysts
182
Total ratings
41.18%
Success rate
-14.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $6.15 | -2.44% | 8 | Feb 28, 2025 | |
FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $4.34 | +522.84% | 9 | Jan 13, 2025 | |
RCKT Rocket Pharmaceuticals | Maintains: Outperform | $46 → $44 | $8.73 | +404.01% | 10 | Nov 19, 2024 | |
LXEO Lexeo Therapeutics | Maintains: Outperform | $20 → $19 | $3.12 | +508.97% | 2 | Nov 13, 2024 | |
NGNE Neurogene | Maintains: Outperform | $45 → $72 | $17.22 | +318.12% | 2 | Nov 12, 2024 | |
CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $5.43 | +213.08% | 1 | Nov 5, 2024 | |
MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $45.18 | +8.46% | 11 | Oct 17, 2024 | |
BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $32.95 | +39.63% | 15 | Oct 17, 2024 | |
WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $10.38 | +112.05% | 6 | Oct 16, 2024 | |
IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $33.00 | +87.88% | 15 | Jul 24, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $15.29 | -14.97% | 1 | Jul 22, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $22.71 | +27.70% | 1 | Jul 2, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $99.54 | +131.06% | 1 | Jun 24, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $3.12 | +28.21% | 2 | Apr 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.52 | - | 10 | Mar 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $5.32 | +483.25% | 1 | Feb 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $23 | $9.12 | +152.19% | 10 | Dec 22, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.68 | +933.36% | 1 | Nov 30, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $15.41 | +159.57% | 12 | May 12, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $35.43 | +162.48% | 17 | Feb 24, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $9.46 | +787.95% | 4 | Jan 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $1.43 | +389.51% | 4 | Jan 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $180 → $160 | $3.78 | +4,134.26% | 10 | Jan 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $25.74 | +199.20% | 2 | Jan 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $240.70 | -40.59% | 11 | Jan 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.38 | +11.52% | 5 | Nov 14, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $43.24 | +75.76% | 1 | Nov 7, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.01 | +3,266.67% | 4 | May 12, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $4.60 | +334.78% | 6 | Jul 23, 2021 |
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $6.15
Upside: -2.44%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $4.34
Upside: +522.84%
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Outperform
Price Target: $46 → $44
Current: $8.73
Upside: +404.01%
Lexeo Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $20 → $19
Current: $3.12
Upside: +508.97%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $17.22
Upside: +318.12%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $5.43
Upside: +213.08%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $45.18
Upside: +8.46%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $32.95
Upside: +39.63%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $10.38
Upside: +112.05%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $33.00
Upside: +87.88%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $15.29
Upside: -14.97%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $22.71
Upside: +27.70%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $99.54
Upside: +131.06%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $3.12
Upside: +28.21%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $7.52
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $5.32
Upside: +483.25%
Dec 22, 2023
Downgrades: Market Perform
Price Target: $23
Current: $9.12
Upside: +152.19%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.68
Upside: +933.36%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $15.41
Upside: +159.57%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $35.43
Upside: +162.48%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $9.46
Upside: +787.95%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $1.43
Upside: +389.51%
Jan 23, 2023
Maintains: Market Perform
Price Target: $180 → $160
Current: $3.78
Upside: +4,134.26%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $25.74
Upside: +199.20%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $240.70
Upside: -40.59%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.38
Upside: +11.52%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $43.24
Upside: +75.76%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.01
Upside: +3,266.67%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $4.60
Upside: +334.78%